Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Stanford University5 sites in 5 countries214 target enrollmentAugust 2007

ConditionsNeoplasms

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Neoplasms
Sponsor: Stanford University
Enrollment: 214
Locations: 5
Primary Endpoint: Percent of patients with evidence of new lesions on combined F-18/F-18 FDG PET/CT.
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Registry

clinicaltrials.gov

Start Date

August 2007

End Date

June 2019

Last Updated

6 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Stanford University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients older than 18-year-old, diagnosed with cancer
•Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them

Exclusion Criteria

•Patients who cannot complete a PET/CT scan
•Pregnant women
•Healthy volunteers
•Patients participating in other research studies
•The subjects will not be paid to participate in this protocol. No costs will be charged to the subjects.